Central administration of GLP-1 and GIP decreases feeding in mice

Biochemical and Biophysical Research Communications

Volumn 490, Issue 2, 2017, Pages 247-252

  NamKoong, Cherl ^a   Kim, Min Sun ^a   Jang, Byeong Tak ^a   Lee, Young Hee ^a   Cho, Young Min ^a   Choi, Hyung Jin ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Gastric inhibitory polypeptide (GIP); Glucagon like peptide 1 amide (GLP 1); Intracerebroventricluar (ICV); Obesity; Pro opiomelanocortin (POMC)

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; PROOPIOMELANOCORTIN; PROTEIN C FOS;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; BODY WEIGHT; CELL POPULATION; DRUG MEGADOSE; DRUG POTENTIATION; FEEDING BEHAVIOR; FLUID INTAKE; FOOD INTAKE; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NERVE CELL NETWORK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EATING; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION;

ANIMALS; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; INFUSIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED C57BL;

EID: 85020784338     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.06.031     Document Type: Article

References (36)

1. Kim, W., Egan, J.M., The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 60:4 (2008), 470–512, 10.1124/pr.108.000604 Epub 2008/12/17 PubMed PMID: 19074620; PubMed Central PMCID: PMC2696340.
2. Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87:4 (2007), 1409–1439, 10.1152/physrev.00034.2006 Epub 2007/10/12. PubMed PMID: 17928588.
3. Cho, Y.M., Fujita, Y., Kieffer, T.J., Glucagon-like peptide-1: glucose homeostasis and beyond. Annu. Rev. Physiol. 76 (2014), 535–559, 10.1146/annurev-physiol-021113-170315 PubMed PMID: 24245943.
4. Bullock, B.P., Heller, R.S., Habener, J.F., Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:7 (1996), 2968–2978, 10.1210/endo.137.7.8770921 Epub 1996/07/01. PubMed PMID: 8770921.
5. Turton, M.D., O'Shea, D., Gunn, I., Beak, S.A., Edwards, C.M., Meeran, K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:6560 (1996), 69–72, 10.1038/379069a0 Epub 1996/01/04. PubMed PMID: 8538742.
6. Tang-Christensen, M., Larsen, P.J., Goke, R., Fink-Jensen, A., Jessop, D.S., Moller, M., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271:4 Pt 2 (1996), R848–R856 Epub 1996/10/01. PubMed PMID: 8897973.
7. Scrocchi, L.A., Brown, T.J., MaClusky, N., Brubaker, P.L., Auerbach, A.B., Joyner, A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2:11 (1996), 1254–1258 Epub 1996/11/01. PubMed PMID: 8898756.
8. Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sorensen, J., Cowley, M.A., Dalboge, L.S., et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Investig. 124:10 (2014), 4473–4488, 10.1172/JCI75276 PubMed PMID: 25202980; PubMed Central PMCID: PMCPMC4215190.
9. Sisley, S., Gutierrez-Aguilar, R., Scott, M., D'Alessio, D.A., Sandoval, D.A., Seeley, R.J., Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Investig. 124:6 (2014), 2456–2463, 10.1172/JCI72434 PubMed PMID: 24762441; PubMed Central PMCID: PMCPMC4038572.
10. Van Gaal, L., Dirinck, E., Pharmacological approaches in the treatment and maintenance of weight loss. Diabetes Care 39:Suppl 2 (2016), S260–S267, 10.2337/dcS15-3016 Epub 2016/07/22. PubMed PMID: 27440841.
11. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373:1 (2015), 11–22, 10.1056/NEJMoa1411892 PubMed PMID: 26132939.
12. Vollmer, K., Holst, J.J., Baller, B., Ellrichmann, M., Nauck, M.A., Schmidt, W.E., et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:3 (2008), 678–687, 10.2337/db07-1124 Epub 2007/12/07. PubMed PMID: 18057091.
13. Cho, Y.M., Kieffer, T.J., K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam. Horm. 84 (2010), 111–150, 10.1016/B978-0-12-381517-0.00004-7 PubMed PMID: 21094898.
14. Usdin, T.B., Mezey, E., Button, D.C., Brownstein, M.J., Bonner, T.I., Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133:6 (1993), 2861–2870, 10.1210/endo.133.6.8243312 Epub 1993/12/01. PubMed PMID: 8243312.
15. Althage, M.C., Ford, E.L., Wang, S., Tso, P., Polonsky, K.S., Wice, B.M., Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 283:26 (2008), 18365–18376, 10.1074/jbc.M710466200 Epub 2008/04/19. PubMed PMID: 18420580; PubMed Central PMCID: PMC2440595.
16. Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8:7 (2002), 738–742, 10.1038/nm727 Epub 2002/06/18. PubMed PMID: 12068290.
17. Ambati, S., Duan, J., Hartzell, D.L., Choi, Y.H., Della-Fera, M.A., Baile, C.A., GIP-dependent expression of hypothalamic genes. Physiological Res./Acad. Sci. Bohemoslovaca 60:6 (2011), 941–950 Epub 2011/10/15. PubMed PMID: 21995902.
18. Kim, S.J., Nian, C., Karunakaran, S., Clee, S.M., Isales, C.M., McIntosh, C.H., GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One, 7(7), 2012, e40156, 10.1371/journal.pone.0040156 PubMed PMID: 22802954; PubMed Central PMCID: PMCPMC3388996.
19. Holscher, C., Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat. CNS Drug Discov. 5:2 (2010), 109–117 PubMed PMID: 20337586.
20. Finan, B., Muller, T.D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R.D., Tschop, M.H., Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol. Med. 22:5 (2016), 359–376, 10.1016/j.molmed.2016.03.005 PubMed PMID: 27038883.
21. Gallwitz, B., Witt, M., Folsch, U.R., Creutzfeldt, W., Schmidt, W.E., Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J. Mol. Endocrinol. 10:3 (1993), 259–268 PubMed PMID: 8396943.
22. Delmeire, D., Flamez, D., Moens, K., Hinke, S.A., Van Schravendijk, C., Pipeleers, D., et al. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. Biochem. Pharmacol. 68:1 (2004), 33–39, 10.1016/j.bcp.2004.02.035 PubMed PMID: 15183115.
23. Lupi, R., Del Guerra, S., D'Aleo, V., Boggi, U., Filipponi, F., Marchetti, P., The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets. Regul. Pept. 165:2–3 (2010), 129–132, 10.1016/j.regpep.2010.04.009 PubMed PMID: 20472004.
24. Gault, V.A., Kerr, B.D., Harriott, P., Flatt, P.R., Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin. Sci. (Lond) 121:3 (2011), 107–117, 10.1042/CS20110006 PubMed PMID: 21332446.
25. Nauck, M.A., Bartels, E., Orskov, C., Ebert, R., Creutzfeldt, W., Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76:4 (1993), 912–917, 10.1210/jcem.76.4.8473405 PubMed PMID: 8473405.
26. Elahi, D., McAloon-Dyke, M., Fukagawa, N.K., Meneilly, G.S., Sclater, A.L., Minaker, K.L., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. 51:1 (1994), 63–74 PubMed PMID: 8036284.
27. Finan, B., Ma, T., Ottaway, N., Muller, T.D., Habegger, K.M., Heppner, K.M., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5(209), 2013, 209ra151, 10.1126/scitranslmed.3007218 Epub 2013/11/01. PubMed PMID: 24174327.
28. Skow, M.A., Bergmann, N.C., Knop, F.K., Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Diabetes Obes. Metab. 18:9 (2016), 847–854, 10.1111/dom.12685 PubMed PMID: 27160961.
29. Tschop, M.H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Muller, T.D., et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 24:1 (2016), 51–62, 10.1016/j.cmet.2016.06.021 PubMed PMID: 27411008.
30. Ciofi, P., The arcuate nucleus as a circumventricular organ in the mouse. Neurosci. Lett. 487:2 (2011), 187–190, 10.1016/j.neulet.2010.10.019 PubMed PMID: 20951768.
31. Kim, M.S., Pak, Y.K., Jang, P.G., Namkoong, C., Choi, Y.S., Won, J.C., et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat. Neurosci. 9:7 (2006), 901–906, 10.1038/nn1731 Epub 2006/06/20. PubMed PMID: 16783365.
32. Kim, M.S., Park, J.Y., Namkoong, C., Jang, P.G., Ryu, J.W., Song, H.S., et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 10:7 (2004), 727–733, 10.1038/nm1061 Epub 2004/06/15. PubMed PMID: 15195087.
33. Fray, P.J., Sahakian, B.J., Robbins, T.W., Koob, G.F., Iversen, S.D., An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69:3 (1980), 253–259 Epub 1980/01/01. PubMed PMID: 6774363.
34. Scott, V., Kimura, N., Stark, J.A., Luckman, S.M., Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J. Neuroendocrinol. 17:7 (2005), 452–457, 10.1111/j.1365-2826.2005.01330.x Epub 2005/06/11. PubMed PMID: 15946163.
35. Naznin, F., Toshinai, K., Waise, T.M., NamKoong, C., Md Moin, A.S., Sakoda, H., et al. Diet-induced obesity causes peripheral and central ghrelin resistance by promoting inflammation. J. Endocrinol. 226:1 (2015), 81–92, 10.1530/JOE-15-0139 PubMed PMID: 26016745; PubMed Central PMCID: PMC4485401.
36. Fenselau, H., Campbell, J.N., Verstegen, A.M., Madara, J.C., Xu, J., Shah, B.P., et al. A rapidly acting glutamatergic ARC–>PVH satiety circuit postsynaptically regulated by alpha-MSH. Natusre Neurosci., 2016, 10.1038/nn. 4442 PubMed PMID: 27869800.